ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells

Push For Smart Industry: ChromoTek wins category "Biotechnology" and the overall first prize from 1200 participating companies.

Visit us at the annual meeting of the American Association for Cancer Research, booth 1038!

ChromoTek's Chromobody® Technology for High Content drug profiling licensed to Bayer